Abstract
Nephrotic syndrome, with or without concomitant tubulointerstitial nephritis, is a rare renal adverse effect of NSAIDs. In the present report we describe a case of a 60-year-old Caucasian man who was admitted because of nephrotic syndrome following several days of use of meloxicam for hip osteoarthritis. Renal histopathology revealed minimal change disease, one of the commonest causes of nephrotic syndrome. The patient’s condition resolved rapidly upon discontinuation of meloxicam. Because he had already experienced two episodes of nephrotic syndrome after administration of diclofenac several years previously, it was concluded that the patient had renal hypersensitivity to both diclofenac and meloxicam. While waiting for the hip arthroplasty, he was prescribed celecoxib for pain control. After 1 month of regular celecoxib use the patient remained in remission with respect to nephrotic syndrome and had normal renal function. We conclude that challenge with a structurally distinct NSAID (such as celecoxib in this case) may be an option, under close surveillance, in a patient with a history of nephrotic syndrome associated with use of an NSAID when continued treatment with an NSAID is indicated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hamza M, Dionne RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2009; 2(1): 1–14
Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006; 2(2): 80–91
Warren GV, Korbet SM, Schwartz MM, et al. Minimal change glomerulopathy associated with nonsteroidal anti-inflammatory drugs. Am J Kidney Dis 1989; 13(2): 127–30
Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28(1 Suppl. 1): S56–62
Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106(5B): 13S–24S
Almansori M, Kovithavongs T, Qarni MU. Cyclooxygenase-2 inhibitor-associated minimal-change disease. Clin Nephrol 2005; 63(5): 381–4
Alper Jr AB, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002; 40(5): 1086–90
Brewster UC, Perazella MA. Acute tubulointerstitial nephritis associated with celecoxib. Nephrol Dial Transplant 2004; 19(4): 1017–8
Demke D, Zhao S, Arellano FM. Interstitial nephritis associated with celecoxib. Lancet 2001; 358(9294): 1726–7
Esteve JB, Launay-Vacher V, Brocheriou I, et al. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. Clin Nephrol 2005; 63(5): 385–9
Henao J, Hisamuddin I, Nzerue CM, et al. Celecoxibinduced acute interstitial nephritis. Am J Kidney Dis 2002; 39(6): 1313–7
Beun GD, Leunissen KM, Van Breda V, et al. Isolated minimal change nephropathy associated with diclofenac. Br Med J (Clin Res Ed) 1987; 295(6591): 182–3
Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs: evidence of a common mechanism. Br J Clin Pharmacol 1999; 47(2): 203–10
Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol 2010; 6(8): 461–70
Mathieson PW. Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 2007; 29(4): 415–26
Cornejo-Garcia JA, Blanca-Lopez N, Dona I, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Drug Metab 2009; 10(9): 971–80
Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001; 357(9272): 1946–7
Alim N, Peterson L, Zimmerman SW, et al. Rofecoxibinduced acute interstitial nephritis. Am J Kidney Dis 2003; 41(3): 720–1
Quiralte J, Blanco C, Delgado J, et al. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. J Investig Allergol Clin Immunol 2007; 17(3): 182–8
Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005; 94(1): 34–8
Senna G, Bilo MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Eur Ann Allergy Clin Immunol 2004; 36(6): 215–8
Viola M, Quaratino D, Gaeta F, et al. Cross-reactive reactions to nonsteroidal anti-inflammatory drugs. Curr Pharm Des 2008; 14(27): 2826–32
Weberschock TB, Muller SM, Boehncke S, et al. Tolerance to coxibs in patients with intolerance to non-steroidal antiinflammatory drugs (NSAIDs): a systematic structured review of the literature. Arch Dermatol Res 2007; 299(4): 169–75
Acknowledgements
No external sources of funding were used to prepare this report. The authors have no conflicts of interests relevant to this work. All authors significantly contributed to the work and met the criteria for authorship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mihovilovic, K., Ljubanovic, D. & Knotek, M. Safe Administration of Celecoxib to a Patient with Repeated Episodes of Nephrotic Syndrome Induced by NSAIDs. Clin. Drug Investig. 31, 351–355 (2011). https://doi.org/10.1007/BF03256934
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256934